# Contact TB-500 Store: Editorial and Correction Inquiries

> Contact TB-500 Store about the TB-500 research digest — editorial questions, corrections, and source suggestions. An editorial project, not a clinic, vendor, or prescription service.

For editorial questions, corrections, and source suggestions on the TB-500 digest. This is an editorial inbox, not a clinical or commercial one.

## What to write about

Use the form below to reach the editorial team behind this TB-500 digest. We welcome corrections, questions about how a study was summarized, and suggestions for peer-reviewed sources we should add. If you believe a citation is wrong or a finding is mischaracterized — particularly where the fragment and full-length thymosin beta-4 might have been conflated — tell us and point us to the source.

What we cannot help with: medical advice, dosing, where to obtain any substance, or clinical consultation. We are an editorial publisher. We do not employ clinicians, we do not sell or dispense anything, and we cannot advise on personal use. Questions of that kind are outside what this project does and outside what it is able to answer.

## How we handle messages

Editorial and correction messages are read and, where a change to the digest is warranted, acted on against the cited source. We do not collect personal health information, and we ask that you not send any. For the regulatory picture that governs access to compounds like this one, the [TB-500 legal status](/legal-status) page is the most complete answer we can offer, and it is general information rather than medical or legal advice.

---

TB-500 Store runs the thymosin beta-4 literature as a single luminous pipeline — the Ac-LKKTETQ fragment traced from actin binding to tissue repair, every full-length-protein substitution flagged in line, the empty human-trial node left lit, and FDA's 503A standing read before anything else; a research repository, not a clinic, a vendor, or a prescription.